Moderna reveals Claudin18.2 ambitions via cancer vaccine, solid tumor CAR-T combo plans
21 Aug 2023
VaccinePhase 3Phase 2Phase 1mRNA
Preview
Source: FierceBiotech
Claudin18.2 is a hot cancer target being chased by Amgen, Astellas, BioNTech and AstraZeneca.
What could be hotter than Moderna getting in the Claudin18.2 race? How about pairing up a newly disclosed mRNA therapeutic cancer vaccine with a solid-tumor-targeting CAR-T?
That sounds like the plan, according to CARsgen Therapeutics. The Chinese biotech is developing CT041, also known as satricabtagene autoleucel, as a Claudin18.2-focused CAR-T for the potential treatment of gastric, pancreatic and other digestive system cancers. Despite being an autologous—as opposed to an allogeneic or “off-the-shelf” therapy—the Shanghai-based company claims that CT041 is the “most advanced solid tumor CAR-T in development” on account of it having entered a “pivotal” phase 2 trial.
The biotech said it has initiated a collaboration agreement with Moderna for the two companies to “contemplate conducting preclinical studies and a phase 1 clinical trial to evaluate CT041 in combination with Moderna’s Claudin18.2 mRNA cancer vaccine.”
Claudin18.2 is a hot cancer target, with Amgen, Astellas and Legend Biotech having thrown a wide spectrum of biologic modalities at it in the belief targeting the tight junction molecule can tackle tumors in the gastrointestinal tract. AstraZeneca has also doubled down on Claudin18.2 this year, paying KYM Biosciences $63 million upfront for the global rights to an early-phase antibody-drug conjugate 10 months after handing over $25 million to Harbour BioMed for a CLDN18.2xCD3 bispecific antibody aimed at the same target.
When it comes to mRNA therapies, Moderna won’t be the first player in the Claudin18.2 space. BioNTech already has a Claudin18.2 inhibitorClaudin18.2 inhibitor called BNT-141 in a phase 1/2 trial for gastric, pancreatic, ovarian and biliary tract tumors.
“Claudin18.2 is a promising therapeutic target to potentially treat multiple cancer types with high unmet medical need,” Moderna’s chief scientific officer of external research ventures Lin Guey, Ph.D., said in this morning’s release.
“We are pleased to partner with CARsgen to explore the potential synergy of CAR-T with an investigational mRNA cancer vaccine that encodes for the Claudin18.2 protein,” Guey added.
Last month, Moderna stirred up interest in another cancer vaccine combo trial when it unveiled details for how it would test a Merck-partnered personalized cancer vaccine with Keytruda in a phase 3 trial for post-surgery treatment of patients with resected melanoma. If eventually successful, Merck and Moderna could open up an entirely new area of cancer treatment.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.